Leadership

Born 1977. Jonas Faijerson Säljö has a research background in the stroke area with wide-ranging experience in the commercialization of medical innovations. Faijerson Säljö has significant expertise in intellectual property and business development experience from a large number of companies in the life science area. He is currently employed as Senior IP Business Consultant and CEO of Synergon AB. Jonas Faijerson Säljö holds a Ph.D. in Neurobiology and is a licensed pharmacist from the University of Gothenburg.

Shareholding: 1,107,904 B shares and 135,440 A shares

Born 1973. Fredrik Frick has extensive experience in research and development and 17 years of combined experience from working at AstraZeneca with early- to late-stage drug development including preclinical target identification, clinical drug discovery, clinical study management and operations and global project management of late-stage projects. Fredrik Frick holds a Ph.D. in Medical Physiology/Endocrinology from the University of Gothenburg.

Shareholding: 300,000 warrants of series 2023/2026

Born 1972. Prof. Michael Holinstat is an Associate Professor in Pharmacology and leads the translational programs in drug development in Hemostasis and Thrombosis in the Department of Pharmacology at the University of Michigan. Prof. Holinstat has built a "state of the art" laboratory to investigate the effects of different pharmacological principles on platelets and coagulation both in vitro and in vivo. Prof. Holinstat is primarily employed as an associate professor at the Department of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery at University of Michigan Medical School. Prof. Holinstat holds a Ph.D. in Pharmacology from the University of Illinois, Chicago, and completed postdoctoral training at Vanderbilt University in Nashville.

Born 1988. Megha Ranjan has nearly a decade of experience supporting small to large-sized global life sciences companies in defining their strategies using comprehensive market insights, intelligence, and valuations. She has previously gained experience from roles in commercial and scientific teams at large pharmaceutical companies including BD&L valuations, real-world evidence analysis, go-to-market strategies, medical affairs and medical information. Megha Ranjan holds a B.Sc. in Dental Surgery and an MBA in Healthcare Management from IIHMR University, India.

Shareholding: 25,000 warrants

Born 1986. Tatiane Abreu Dall’Agnol is a medical doctor with nearly a decade of clinical experience. She has previously also worked as a life science consultant advising biotech companies on drug development strategy and analysis; and gained experience in business development and competitive intelligence at Pieris Pharmaceuticals. Tatiane has a medical degree from the Universidade Positivo, Curitiba, PR, Brazil, and an M.Sc. in Business Creation and Entrepreneurship in Biomedicine from the University of Gothenburg, Sweden.

Shareholding: 200,000 warrants

J. Donald (Don) de Bethizy, PhD has more than 30 years of experience in managing and financing life science-related technologies and has played a key role in building and advising several life sciences companies. Don de Bethizy advised the CEO and board of NDA Group AB one of the world’s leading private biotechnology regulatory consulting firms until its sale to SSI Strategy in 2023. In 2017, Don facilitated the management buyout of Albumedix Ltd from Novozymes A/S and the subsequent sale of Albumedix Ltd to Sartorius for 415 MGBP in late 2022. He is currently President of White City Consulting ApS (Denmark), a Director at Lophora ApS (Denmark) and Proterris Inc (USA), as well as Vice Chair of the board of argenx NV a global commercial immunology company headquartered in Gent, Belgium with 2023 sales of 1.2 BUSD of its first drug Vyvgart in the rare autoimmune disease myasthenia gravis. In 2014, in his role as Chief Executive Officer of the Danish biotech Santaris Pharma A/S, he led the sale of the company to Roche for 450 MUSD. He co-founded Targacept, Inc. and served as its President and Chief Executive Officer for 15 years. Don de Bethizy led Targacept’s private and US Nasdaq public financings totaling approximately 330 MUSD, including the Company’s Initial Public Offering (IPO) in April 2006. Don de Bethizy holds a B.S. in Biology from the University of Maryland and an M.S. and PhD in Toxicology from Utah State University.

Born 1962. Øvlesen has experience in business development and has been involved in more than 20 successful start-ups in medtech, biotech, and IT, including CLC Bio, Cetrea and Monsenso. Øvlesen is Co-founder, board member and CEO at SynAct Pharma AB (publ), and has previously been CEO at ChemoMetec A/S and PNN Medical A/S. Previous experience also includes founding TXP Pharma, and holding executive positions as CFO and Vice President of business development at Action Pharma A/S, whose lead candidate was sold to AbbVie for 110 MUSD. Øvlesen is currently chairman in HG Energy Group A/S, Cercare Medical A/S, Go-Pen A/S, and Neurescue ApS, and is a board member in Perfusion Tech Aps, and ResoTher Pharma Aps. Øvlesen has an MBA with a focus on leadership and finance from the University of Hartford, US. He was a Board member of Cereno Scientific from 2023-2025.

Considered dependent of the company, but independent of its management and major shareholders.

Shareholding: 85,234 Class B Shares and 1,000,000 warrants.

Born 1987. Moi Brajanovic has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. He is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. Moi holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg.

Considered independent of the company, its management and major shareholders.

Shareholding: 407,000 Class B shares

Born 1953. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. He was previously Adjunct Professor at the Karolinska Institute and has extensive experience from leading R&D positions in the pharmaceutical industry. He has over 20 years of experience in different Global R&D management positions at AstraZeneca and contributed to more than a dozen successful global product registrations for medicines in cardiovascular, vascular and gastrointestinal indications. Dr. Gunnar Olsson has been on the board of ESC, that awarded him the ESC President Award in recognition of his outstanding lifetime achievements, in 2023. He was a board member in Cereno Scientific between 2016-2018 and has been a member of the Scientific Advisory Board since this was established in 2019. Dr. Gunnar Olsson has been a senior advisor to the executive management team since 2018. Olsson is a Board member of IRLAB Therapeutics AB and Amplifier Tx AB. He is Vice Chair for the Swedish Heart Lung Foundation and Bundy Academy, Lund University.

Considered independent of the company, its management and major shareholders.

Shareholding: 5,000 Class B shares and 600,000 warrants.

Born 1951. Dr. Anders Svensson is a licensed physician, medical doctor, and lecturer with over 20 years of experience in academic medicine; his scientific focus is cardiovascular diseases. He has extensive experience in international pharmaceutical development after almost 20 years in leading positions within the global pharmaceutical industry such as F. Hoffmann-LaRoche where he was responsible for the global clinical development of diabetes and cardiovascular. Prior to that he was working as Vice President and responsible for the clinical development of cardiovascular and later gastrointestinal drugs at AstraZeneca. Anders Svensson has almost 100 publications to his name. Anders Svensson holds a MD, Ph.D. from the University of Gothenburg. He is founder of C Anders Svensson Consulting.

Considered independent of the company, its management and major shareholders.

Shareholding: 488,200 B shares and 1,100,000 warrants

Sten R. Sörensen has been the CEO of Cereno Scientific since 2015 and has extensive experience from the pharma, biotech, and finance industries. Prior to Cereno Scientific, he held senior positions in major pharma including Head of International Marketing Operations for the 10 BSEK pharma portfolio at Monsanto and Global Marketing Director for the 4 BSEK portfolio of Secondary Prevention Products, Cardiovasculars at AstraZeneca. At Monsanto and AstraZeneca, he initiated two groundbreaking preventive survival studies in heart failure, RALES and MERIT-HF, both establishing a paradigm shift for mineralocorticoid receptor (MR) antagonism and beta-blocker drug therapies in heart failure, significantly improving quality of life and life expectancy. He was also a Board member of Cereno Scientific between 2014-2016. Sten holds a bachelor’s degree in chemistry from Lund University. He is the Chairman of SARomics Biostructure and board member of SynAct Pharma.

Considered dependent of the company and its management, but independent of major shareholders.

Shareholding: 1,995,179 Class B shares and 5,000,000 warrants

Dr. Pitt is a Professor Emeritus in Medicine at the University of Michigan School of Medicine, US. Pitt assumed directorship of the division of Cardiology at the University of Michigan School of Medicine in 1977. Among his achievements, he has been awarded the James B Herrick award from the American Heart Association as well as life-time achievement awards from the Heart Failure Society of America and the European Heart Failure Society. He has served on the editorial boards of several cardiovascular journals and has published over 750 articles, chapters and books. Co-chairman, CVCT Global Forum.

Dr. Benza is currently Section Chief of Cardiology at the Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School at Old Dominion University and the George and Linda Kaufman Academic Chair of Cardiology at Sentara Health in Norfolk, Virginia, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board. He has extensive clinical trial experience with involvement in just over 60 different clinical trials. Dr. Benza has also been involved in around 325 publications and written 6 books of which 3 are focused on pulmonary hypertension.

Dr. Deepak Bhatt was Professor of Medicine at Harvard Medical School between 2012–2022. He has been listed in Best Doctors in America from 2005 to 2020. Dr. Bhatt has authored or co-authored over 1900 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2022. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease.

Born 1953. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. He was previously Adjunct Professor at the Karolinska Institute and has extensive experience from leading R&D positions in the pharmaceutical industry. He has over 20 years of experience in different Global R&D management positions at AstraZeneca and contributed to more than a dozen successful global product registrations for medicines in cardiovascular, vascular and gastrointestinal indications. Dr. Gunnar Olsson has been on the board of ESC, that awarded him the ESC President Award in recognition of his outstanding lifetime achievements, in 2023. He was a board member in Cereno Scientific between 2016-2018 and has been a member of the Scientific Advisory Board since this was established in 2019. Dr. Gunnar Olsson has been a senior advisor to the executive management team since 2018. Olsson is a Board member of IRLAB Therapeutics AB and Amplifier Tx AB. He is Vice Chair for the Swedish Heart Lung Foundation and Bundy Academy, Lund University.

Considered independent of the company, its management and major shareholders.

Shareholding: 5,000 Class B shares and 600,000 warrants.

Dr. Williams is a Professor of Medicine at Harvard Medical School since 1981 and was the founder and Director of its Scholars in Clinical Science Program until 2008. A lifelong interest of Williams has been to understand the mechanisms by which aldosterone participates in cardiovascular diseases. He has published more than 600 original articles, reviews, chapters and books, including co-editing his seminal textbook “Clinical and Translational Science.”

Dr. Zannad is a Professor Emeritus of Therapeutics and Cardiology at Université de Lorraine, France. Zannad is involved in a number of major cardiovascular clinical trials, as a Principal Investigator and/or as a chair or member of several Steering Committees, Critical Event Committees and Data Safety and Monitoring Boards. Founder & chairman, CVCT Global Forum.